Tokyo, Japan
NCT Number: NCT01115985
A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Atorvastatin in Healthy Volunteers
This study is to assess the effect of ASP1585 on pharmacokinetics of atorvastatin in 2x2 crossover method.
Looking for future studies?
Notify MeKey information
Conditions
Age range
20 year–44 year
Sex eligibility
Male
Study type
Interventional
Phase
Phase 1
Primary location
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Body weight: =<50.0kg, <80.0kg
- Body mass index: =<17.6, <26.4
- Healthy as judged by investigator or caregiver from subjective and objective symptoms and physical examination data
Exclusion criteria
- Attending another clinical trial within 120 days before the study
- Blood donation within 90 days (400ml) or 30 days (200ml) before the study
- Receiving any drugs within 7 days before the study
- History of allergy to drugs
- Having GI disorders
- History or complication of liver diseases
- History or complication of heart disease
- History or complication of respiratory diseases
- History or complication of renal diseases
- History or complication of cerebrovascular diseases
Treatment and study plan
ASP1585
Drugoral
atorvastatin
Drugoral
Other names: Lipitor
Primary outcomes
-
Plasma concentration of atorvastatin
Time frame: 48 hours after administration
Secondary outcomes
-
Safety assessed by AE, vital signs 12-lead ECG and lab tests
Time frame: 7 days after administration
Sponsors and collaborators
Lead sponsor
Astellas Pharma Inc
Industry
Registry information
Official study title
ASP1585 Pharmacokinetic Interaction Study - Pharmacokinetic Interaction With Atorvastatin -
Important dates
- Study start
- 2010
- Primary completion
- 2010
- Study completion
- 2010
- First posted
- May 4, 2010
- Registry last updated
- May 27, 2010
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Phase I Study With V-212 Vaccinations in Healthy Adult Volunteers
NCT06975319
Healthy, Immunisation Against Streptococcus Pneumoniae
Ghent, Belgium
View Trial DetailsA Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
NCT06945419
Body Weight, Body Weight Changes
Daytona Beach, Florida, United States
View Trial DetailsMAD Study of IA-14069
NCT05533372
Arthritis, Arthritis, Rheumatoid
Lenexa, Kansas, United States
View Trial DetailsA Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function
NCT06916078
Digestive System Diseases, Healthy
Miami, Florida, United States
View Trial Details